WednesdaySep 14, 2022 12:35 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S.…

Continue Reading

ThursdaySep 08, 2022 1:40 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S.…

Continue Reading

ThursdayAug 25, 2022 1:26 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research

Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’” a recent article reads. According to Silo Pharma CEO Eric Weisblum, the company is encouraged by the progress and looks forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of…

Continue Reading

FridayAug 12, 2022 2:58 pm

PsychedelicNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its…

Continue Reading

ThursdayAug 04, 2022 1:16 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes

Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug,” a recent article reads. “In addition, Silo recently announced…

Continue Reading

WednesdayAug 03, 2022 2:35 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition of a phase 1 N,N-Dimethyltryptamine (“N,N-DMT”) study, the largest DMT study to date. The study provides key data relating to the company’s proprietary CYB004 substance with the potential to effectively treat anxiety disorders. “The phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary… The adaptive, randomized, double-blinded, placebo-controlled, single-ascending-dose study produced notable results. According to the…

Continue Reading

FridayJul 22, 2022 1:50 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology

Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side effects that include nausea, vomiting, diarrhea, tinnitus, hair loss, seizures, fever, congestion, unusual lumps or masses, and more. OTC arthritis therapeutics, such as common NSAIDs, can produce stomach ulcers, dizziness and indigestion and can have…

Continue Reading

WednesdayJul 20, 2022 3:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research,” a recent article reads.…

Continue Reading

FridayJul 08, 2022 2:54 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients

Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine Ann Denny, an associate professor of clinical neurobiology, saying: “To bring hope and possibly a therapeutic to patients suffering from Alzheimer’s Disease is an exciting proposition for Silo Pharma.” Alongside its work with Columbia University, Silo has partnered with Zylo Therapeutics to use Zylo’s Z-pod…

Continue Reading

WednesdayJun 15, 2022 3:10 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050